Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial
Gastric Cancer · 2026
DOI: 10.1007/s10120-025-01692-w ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Gastric Cancer, 2026. Verfasst von Ryohei Kawabata und 10 weiteren Autor:innen. Beteiligte Einrichtung: Osaka Rosai Hospital, Sakai, Japan. r-kawabata@umin.ac.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Irinotecan, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Eli Lilly Japan.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: In late-line treatment for advanced gastric cancer (AGC), evidence supporting the use of irinotecan in older patients remains limited. We conducted a post-hoc age-subgroup analysis of the phase III RINDBeRG study, which randomized AGC patients previously treated with ramucirumab-based chemotherapy to receive ramucirumab plus irinotecan (RAM + IRI) or irinotecan alone (IRI). METHODS: Patients were classified as elderly (≥ 70 years; n = 83 [RAM + IRI], 80 [IRI]) or non-elderly (< 70 years; n = 117, 113). Efficacy outcomes-including overall survival (OS), progression-free survival (PFS), and overall response rate (ORR)-and safety were compared. Prognostic factors for OS were explored via multivariable Cox regression. RESULTS: OS and PFS did not differ significantly between age groups. In the RAM + IRI group, median OS was 9.7 vs. 8.9 months (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.63-1.15), and PFS was 4.0 vs. 3.6 months (HR 0.84, CI 0.63-1.12). In the IRI group, OS was 8.5 months in both groups (HR 0.99, CI 0.7-1.34), and PFS was 3.1 vs. 2.2 months (HR 0.87, CI 0.65-1.17). ORRs were 20.5% vs. 14.5% (RAM + IRI) and 18.8% vs. 9.7% (IRI) in elderly vs. non-elderly patients. Grade ≥ 3 adverse events were comparable. Multivariable analysis identified ECOG PS 1, peritoneal metastasis, elevated LDH, modified Glasgow Prognostic Score ≥ 1, and low alkaline phosphatase as poor prognostic factors. Age was not prognostic. CONCLUSIONS: Irinotecan-based therapy offers comparable efficacy and tolerability in older and younger patients with refractory AGC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Osaka Rosai Hospital, Sakai, Japan. r-kawabata@umin.ac.jp.
- Department of Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-Cho, Nishi-Ku, Sakai-City, Osaka, 5938304, Japan. r-kawabata@umin.ac.jp.
- The University of Osaka Hospital, Suita, Japan.
- Osaka International Cancer Institute, Osaka, Japan.
- Wakayama Medical University, Wakayama, Japan.
- Toranomon Hospital, Tokyo, Japan.
ORCID-Profile: Ryohei Kawabata
Förderung
- Eli Lilly Japan
Zitieren
APA
Kawabata, R., Sakai, D., Shimokawa, T., Kizawa, R., Ishiguro, T., Yukami, H., Boku, S., Yamaguchi, T., Endo, S., Tsujinaka, T., & Satoh, T. (2026). Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial. Gastric Cancer. https://doi.org/10.1007/s10120-025-01692-w
Vancouver
Kawabata R, Sakai D, Shimokawa T, Kizawa R, Ishiguro T, Yukami H, et al. Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial. Gastric Cancer. 2026. doi:10.1007/s10120-025-01692-w
BibTeX
@article{Kawabata2026,
author = {Kawabata, Ryohei and Sakai, Daisuke and Shimokawa, Toshio and Kizawa, Rika and Ishiguro, Toru and Yukami, Hiroki and Boku, Shogen and Yamaguchi, Toshifumi and Endo, Shunji and Tsujinaka, Toshimasa and Satoh, Taroh},
title = {Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial},
journal = {Gastric Cancer},
year = {2026},
doi = {10.1007/s10120-025-01692-w}
}
EUVIMED